Axonis Therapeutics (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- November 04, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $115,000,000
Company Info
- Company Description
- Axonis Therapeutics is a biotechnology company focused on the development of novel neuromedicines. The company is advancing its lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for inhibitory neurotransmission, for the treatment of epilepsy and pain.
- Market
- Neuromedicines
- Location
- Boston, MA, USA
- Coinvestors
- Cormorant Asset Management, venBio Partners, Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, Lumira Ventures, Solasta Ventures